Glenmark Pharma has received a warning letter from the U.S. FDA related to its Baddi facility in India. The warning letter follows an inspection of the facility by the FDA April 15 and April 20, after which the regulator issued a Form 483 with eight observations. The company said that it is in the process of preparing a detailed response to the FDA within 15 working days. For its part Glenmark notes in a statement that they do not expect the warning letter to adversely impact the existing manufacturing of product s at the facility and note that there are no major approvals pending at this facility for the next 12 months. Learn More